Knight Therapeutics: Stocks Analysts Recently Downgraded on TSX (GUD)
Knight Therapeutics is among the group of Toronto Stock Exchange stocks recently downgraded by analysts. This means each stock on this list has seen its averge consensus value drop in the last week so at least one analyst has downgraded their view on these stocks.
This report is generated monthly. It displays the number of analysts along with their buy-hold-sell ratings for the company. A company is included in this list when its mean rating decreases from the previous week. Stocks in this category are generally sold to preserve capital. Companies can get downgraded for a number of reasons - but primarily due to reduced future earnings potential due to loss of contracts, new faltering product lines or increasing costs relative to revenue or financial risk.
| Symbol | Name | Buy | Out Perform | Hold | Under Perform | Sell | No Opinion | Mean Rating | Previous Mean Rating | Mean Label |
|---|---|---|---|---|---|---|---|---|---|---|
| NWH-UN-T | Northwest Healthcare Properties Real Estate Investment Trust | 2 | 1 | 3 | 0 | 0 | 0 | 3 | 3 | Outperform |
| CS-T | Capstone Copper Corp | 3 | 3 | 0 | 0 | 0 | 0 | 4 | 4 | Outperform |
| STLC-T | Stelco Holdings Inc | 2 | 1 | 4 | 0 | 0 | 0 | 3 | 3 | Outperform |
| GUD-T | Knight Therapeutics Inc | 3 | 0 | 3 | 0 | 0 | 0 | 4 | 5 | Outperform |
More about Knight Therapeutics Inc
Knight Therapeutics Inc operates in the healthcare sector. It is a specialty and generic drug manufacturing company. It deals mainly in pharmaceutical products, consumer health products and medical devices.
Artificial intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
